Resorcinol

RTECS #

VG9625000

CAS #

108-46-3
See: NMAM or OSHA Methods

Updated

March 2019

Molecular Weight

110.12

Molecular Formula

C₆H₆O₂

Synonyms

1,3-Benzenediol
1,3-Dihydroxybenzene
3-Hydroxycyclohexadien-1-one
3-Hydroxyphenol
Benzene, m-dihydroxy-
C.I. 76505
C.I. Developer 4
C.I. Oxidation Base 31
Developer O
Developer R
Developer RS
Durafur developer G
Fouramine RS
Fourrine 79
Fourrine EW
m-Benzenediol
m-Dihydroxybenzene
m-Dioxybenzene
m-Hydroquinone
m-Hydroxyphenol
Nako TGG
NCI-C05970
Pelagol Grey RS
Pelagol RS
Phenol, m-hydroxy-
RCRA waste number U201
Resorcin
Resorcine
Resorcinol (ACGIH)

Skin and Eye Irritation and References

Route/Organism	Dose	Effect	Reference
eye /rabbit	100 mg	severe	HPV370 -,-,2004
eye /rabbit	100 mg rinse	severe	HPV370 -,-,2004
skin /rabbit	500 mg		IHFCAY 6,1,1967
skin /rabbit	20 mg/24H	moderate	85JCAE -,234,1986
skin /rabbit	500 mg	severe	HPV370 -,-,2004

Mutation Data and Reference

System Test	Route/Organism/Tissue	Dose	Reference
Cytogenetic Analysis	lymphocyte/human	80 mg/L	ARZNAD 32,533,1982
Cytogenetic Analysis	other cell types/human	40 mg/L	ARZNAD 32,533,1982
Cytogenetic Analysis	ovary/hamster	1600 mg/L	CALEDQ 14,251,1981
Cytogenetic Analysis	lymphocyte/human	0.002 pph	VCVGK* -,227,1994
Cytogenetic Analysis	ovary/hamster	1600000 µg/L (+/-enzymatic activation step)	HPV370 -,-,2004
DNA Damage	other cell types/mouse	0.31 mmol/L	MUREAV 715,25,2011
DNA Damage	liver/rat	10 mmol/L	CALEDQ 63,47,1992
DNA Damage	other cell types/human	1000 µmol/L/24H	MUTAEX 31,83,2016
DNA Damage	mammary gland/human	50 mg/L/24H (-enzymatic activation step)	MUREAV 588,47,2005
gene conversion and mitotic recombination	/Saccharomyes cerevisiae	1 gm/L	MUREAV 135,109,1984
micronucleus test	ovary/hamster	186 mg/L/24H (-enzymatic activation step)	MUREAV 582,116,2005
micronucleus test	ovary/hamster	372 mg/L/3H (+enzymatic activation step)	MUREAV 582,116,2005
micronucleus test	lung/hamster	196 mg/L/3H (+enzymatic activation step)	MUREAV 742,11,2012
micronucleus test	liver/human	377 mg/L/3H (+enzymatic activation step)	MUREAV 742,11,2012
micronucleus test	lymphocyte/mouse	200 mg/L/3H	MUREAV 789,7,2015
micronucleus test	other cell types/human	100 mg/L/3H	MUREAV 789,7,2015
mutation in microorganisms	/Salmonella typhimurium	3600 µg/plate (-enzymatic activation step)	HPV370 -,-,2004
mutation in microorganisms	/Salmonella typhimurium	3600 µg/plate (+enzymatic activation step)	HPV370 -,-,2004
mutation in microorganisms	/Salmonella typhimurium	20 µmol/plate (+/-enzymatic activation step)	MUREAV 90,91,1981
other mutation test systems	other cell types/human	2500 µmol/L	TIVIEQ 29,1425,2015
specific locus test	other cell types/human	1000 µmol/L/24H	EMMUEG 54,737,2013

Tumorigenic Data and References

Route/Organism	Dose	Effect	Reference
oral/rat	lowest published toxic dose: 137200 mg/kg/49W- intermittent	Tumorigenic: Neoplastic by RTECS criteria Gastrointestinal: Tumors Tumorigenic: Increased incidence of tumors in susceptible strains	HPV370 -,-,2004
skin/mouse	lowest published toxic dose: 4800 mg/kg/12W- intermittent	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Skin and Appendages: Tumors	CNREA8 19,413,1959

Acute Toxicity Data and References

Route/Organism	Dose	Effect	Reference
In Vitro/Human, leukemia cells	Inhibitor Concentration (25 percent kill): 613.4 mg/L/24H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TIVIEQ 26,1150,2012
In Vitro/Human, leukemia cells	Inhibitor Concentration (25 percent kill): 275 mg/L/48H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 30,318,2015
In Vitro/Human, leukemia cells	Inhibitor Concentration Low: 275 mg/L/48H	Immunological Including Allergic: Increase in cellular immune response	TIVIEQ 30,318,2015
In Vitro/Human, leukemia cells	Inhibitor Concentration Low: 275 mg/L/24H	Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation	TIVIEQ 30,318,2015
In Vitro/Human, lymphocyte	Inhibitor Concentration (30 percent kill): 173 mg/L/45H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TIVIEQ 29,901,2015
In Vitro/Human, lymphocyte	Inhibitor Concentration (50 percent kill): 5 mg/L/45H	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,901,2015
In Vitro/Human, melanoma	Inhibitor Concentration (50 percent kill): 127.3 mg/L/48H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	FCTOD7 50,2084,2012
In Vitro/Human, monocyte	Inhibitor Concentration Low: 4955 mg/L/2H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1233,2013
In Vitro/Human, skin	Inhibitor Concentration (20 percent kill): 55.1 mg/L/21H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,314,2013
In Vitro/Human, skin	Inhibitor Concentration Low: 55.1 mg/L/4H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,314,2013
In Vitro/Human, skin	Inhibitor Concentration (20 percent kill): 206.0 mg/L/24H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1127,2013
In Vitro/Human, skin	Inhibitor Concentration (20 percent kill): 500 mg/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,1135,2013
In Vitro/Human, skin	Inhibitor Concentration Low: 125 mg/L/24H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1135,2013
In Vitro/Human, skin	Inhibitor Concentration (50 percent kill): 68.58 gm/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,1135,2013
In Vitro/Human, skin	Inhibitor Concentration (50 percent kill): 1126.6 µmol/L/48H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 29,688,2015
In Vitro/Human, skin	Inhibitor Concentration (50 percent kill): >2000 µmol/L/48H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.	TIVIEQ 29,688,2015
In Vitro/Human, skin	Inhibitor Concentration (30 percent kill): 623 µmol/L/48H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 29,688,2015
In Vitro/Human, skin	Inhibitor Concentration (30 percent kill): 1623.9 µmol/L/48H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.	TIVIEQ 29,688,2015
In Vitro/Human, skin	Inhibitor Concentration (50 percent kill): 906.8 µmol/L/48H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	TIVIEQ 29,688,2015
intraperitoneal/mouse	lethal dose (50 percent kill): 215 mg/kg		HPV370 -,-,2004
intravenous/Dog	lowest published lethal dose: 700 mg/kg		VCVGK* -,227,1994
oral/human	lowest published lethal dose: 29 mg/kg		34ZIAG -,519,1969
oral/mouse	lethal dose (50 percent kill): 200 mg/kg		JJTOEX 4,105,1991
oral/rat	lowest published lethal dose: 300 mg/kg	Behavioral: Convulsions or effect on seizure threshold Lung, Thorax, or Respiration: Dyspnea	RTOPDW 36,198,2002
oral/rat	lethal dose (50 percent kill): 202 mg/kg		HPV370 -,-,2004
oral/rat	lowest published lethal dose: 215 mg/kg	Behavioral: Convulsions or effect on seizure threshold Lung, Thorax, or Respiration: Other changes Blood: Hemorrhage	HPV370 -,-,2004
parenteral/frog	lowest published lethal dose: 270 mg/kg	Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change Behavioral: Convulsions or effect on seizure threshold Cardiac: Other changes	AEPPAE 166,437,1932
skin/mouse	lowest published lethal dose: 340 mg/kg		VCVGK* -,226,1994
skin/rabbit	lethal dose (50 percent kill): 3360 mg/kg	Skin: After topical application: Primary irritation Nutritional and Gross Metabolic: Weight loss or decreased weight gain	AIHAAP 37,596,1976
skin/rabbit	lethal dose (50 percent kill): 3360 mg/kg	Skin: After topical application: Primary irritation	HPV370 -,-,2004
skin/rabbit	lowest published lethal dose: 3360 mg/kg		RTOPDW 36,198,2002
skin/rabbit	lethal dose (50 percent kill): 3360 mg/kg		VCVGK* -,227,1994
subcutaneous/cat	lowest published lethal dose: 110 mg/kg		VCVGK* -,227,1994
subcutaneous/cat	lowest published lethal dose: 110 mg/kg	Behavioral: Convulsions or effect on seizure threshold Blood: Methemoglobinemia- Carboxhemoglobinemia	AEXPBL 72,241,1913
subcutaneous/guinea pig	lowest published lethal dose: 400 mg/kg	Behavioral: Excitement Behavioral: Tetany Behavioral: Coma	RMSRA6 15,561,1895
subcutaneous/guinea pig	lowest published lethal dose: 400 mg/kg		VCVGK* -,227,1994
subcutaneous/mouse	lethal dose (50 percent kill): 213 mg/kg		HPV370 -,-,2004
subcutaneous/rat	lowest published lethal dose: 400 mg/kg		VCVGK* -,227,1994
subcutaneous/rat	lowest published lethal dose: 400 mg/kg	Behavioral: Excitement Behavioral: Tetany Behavioral: Coma	RMSRA6 15,561,1895
subcutaneous/rat	lethal dose (50 percent kill): 450 mg/kg		HPV370 -,-,2004

Other Multiple Dose Data and References

Route/Organism	Dose	Effect	Reference
inhalation/rat	lowest published toxic concentration: 7800 mg/m³/90D- continuous	Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	HPV370 -,,2004
oral/mouse	lowest published toxic dose: 3000 mg/kg/2W- continuous	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	HPV370 -,,2004
oral/mouse	lowest published toxic dose: 115875 mg/kg/103W- intermittent	Skin and Appendages: Tumors Tumorigenic: Active as anti-cancer agent	NTIS** PB93-126381
oral/mouse	lowest published toxic dose: 3600 mg/kg/17D- intermittent	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	NTPTR* NTP-TR-403,1992
oral/mouse	lowest published toxic dose: 27300 mg/kg/13W- intermittent	Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	NTPTR* NTP-TR-403,1992
oral/rat	lowest published toxic dose: 25750 mg/kg/103W- intermittent	Skin and Appendages: Tumors Tumorigenic: Active as anti-cancer agent	NTIS** PB93-126381
oral/rat	lowest published toxic dose: 150 mg/kg/30D- intermittent	Endocrine: Thyroid weight (goiter) Endocrine: Evidence of thyroid hypofunction	RTOPDW 36,198,2002
oral/rat	lowest published toxic dose: 33800 mg/kg/13W- continuous	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	HPV370 -,,2004
oral/rat	lowest published toxic dose: 5915 mg/kg/13W- intermittent	Liver: Changes in liver weight Endocrine: Changes in adrenal weight	RTOPDW 36,198,2002
oral/rat	lowest published toxic dose: 47320 mg/kg/13W- intermittent	Liver: Changes in liver weight Endocrine: Changes in adrenal weight Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	RTOPDW 36,198,2002
oral/rat	lowest published toxic dose: 35000 mg/kg/2W- continuous	Endocrine: Evidence of thyroid hypofunction Endocrine: Changes in thyroid weight Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)	HPV370 -,,2004
oral/rat	lowest published toxic dose: 5400 mg/kg/17D- intermittent	Endocrine: Changes in thymus weight	NTPTR* NTP-TR-403,1992
skin/rat	lowest published toxic dose: 21000 mg/kg/4W- intermittent	Endocrine: Thyroid weight (goiter)	RTOPDW 36,198,2002
subcutaneous/rat	lowest published toxic dose: 20700 mg/kg/69D- intermittent	Endocrine: Thyroid weight (goiter)	RTOPDW 36,198,2002

Reviews

Organization	Standard	Reference
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-time-weighted average 10 ppm;short term exposure limit 20 ppm	DTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-Not classifiable as a human carcinogen	DTLVS* TLV/BEI,2013
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Inadequate Evidence	IMEMDT 15,155,1977
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Inadequate Evidence	IMEMDT 71,1119,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Human No Adequate Data	IMEMDT 15,155,1977
International Agency for Research on Cancer (IARC)	Cancer Review:Human No adequate Data	IMEMDT 71,1119,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Group 3	IMEMDT 71,1119,1999
TOXICOLOGY REVIEW		MUREAV 47,75,1978
TOXICOLOGY REVIEW		JACTDZ 5(3),167,1986
TOXICOLOGY REVIEW		MUREAV 543,201,2003
TOXICOLOGY REVIEW		EMMUEG 39,69,2002
TOXICOLOGY REVIEW		JEADV* 13,14,1999
TOXICOLOGY REVIEW		MUREAV 584,1,2005
TOXICOLOGY REVIEW		EMCNA* 25,375,2007
TOXICOLOGY REVIEW		TXAPA9 243,239,2010
TOXICOLOGY REVIEW		MUREAV 723,101,2011
TOXICOLOGY REVIEW		MUREAV 653,99,2008
TOXICOLOGY REVIEW		REPTED 33,188,2012
TOXICOLOGY REVIEW		FCTOD7 49,2495,2011
TOXICOLOGY REVIEW		MUREAV 795,7,2016
TOXICOLOGY REVIEW		FCTOD7 94,93,2016
TOXICOLOGY REVIEW		MUREAV 802,1,2016
TOXICOLOGY REVIEW		MUTAEX 31,347,2016
TOXICOLOGY REVIEW		MUTAEX 32,491,2017
TOXICOLOGY REVIEW		RTOPDW 61,1,2011

Standards and Regulations

Organization	Standard	Reference
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIA	time-weighted average 10 ppm (45 mg/m³), short term exposure limit 20 ppm (90 mg/m³), JUL2008
Occupational Exposure Limit-AUSTRIA	MAK-TMW 10 ppm (45 mg/m³), skin, 2007
Occupational Exposure Limit-BELGIUM	time-weighted average 10 ppm (46 mg/m³), MAR2002
Occupational Exposure Limit-BELGIUM	short term exposure limit 20 ppm (91 mg/m³), Skin, MAR2002
Occupational Exposure Limit-DENMARK	time-weighted average 10 ppm (45 mg/m³), skin, MAY2011
Occupational Exposure Limit-EC	time-weighted average 45 mg/m³ (10 ppm), skin, FEB2006
Occupational Exposure Limit-FINLAND	time-weighted average 10 ppm (46 mg/m³), short term exposure limit 20 ppm (91 mg/m³), NOV2011
Occupational Exposure Limit-FRANCE	VME 10 ppm (45 mg/m³), FEB2006
Occupational Exposure Limit-HUNGARY	time-weighted average 45 mg/m³, Skin, SEP2000
Occupational Exposure Limit-ICELAND	time-weighted average 10 ppm (45 mg/m³), skin, NOV2011
Occupational Exposure Limit-JAPAN	s1 sen, MAY2012
Occupational Exposure Limit-KOREA	time-weighted average 10 ppm (45 mg/m³), short term exposure limit 20 ppm (90 mg/m³), 2006
Occupational Exposure Limit-MEXICO	time-weighted average 10 ppm (45 mg/m³);short term exposure limit 20 ppm (90 mg/m³), 2004
Occupational Exposure Limit-NEW ZEALAND	time-weighted average 10 ppm (45 mg/m³), short term exposure limit 20 ppm (90 mg/m³), JAN2002
Occupational Exposure Limit-PERU	time-weighted average 10 ppm (45 mg/m³); short term exposure limit 20 ppm (90 mg/m³), JUL2005
Occupational Exposure Limit-POLAND	MAC(time-weighted average) 45 mg/m³, MAC(short term exposure limit) 90 mg/m³, JAN1999
Occupational Exposure Limit-RUSSIA	short term exposure limit 5 mg/m³, Skin, JUN2003
Occupational Exposure Limit-SWEDEN	time-weighted average 10 ppm (45 mg/m³), Skin, JUN2005
Occupational Exposure Limit-SWITZERLAND	MAK-week 10 ppm, JAN2011
Occupational Exposure Limit-THE NETHERLANDS	MAC-TGG 45 mg/m³, 2003
Occupational Exposure Limit-UNITED KINGDOM	time-weighted average 10 ppm (46 mg/m³);short term exposure limit 20 ppm (92 mg/m³), OCT2007

NIOSH Documentation and Surveillance

Organization	Standard	Reference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO RESORCINAL-air	10H time-weighted average 10 ppm;short term exposure limit 20 ppm	NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983	Hazard Code 67220; Number of Industries 30; Total Number of Facilities 6842; Number of Occupations 43; Total Number of Employees Exposed 100792; Total Number of Female Employees Exposed 56465
National Occupational Hazard Survey 1974	Hazard Code 67220; Number of Industries 45; Total Number of Facilities 4488; Number of Occupations 42; Total Number of Employees Exposed 40431

Status in Federal Agencies

Organization	Reference
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus
EPA GENETOX PROGRAM 1988, Negative: N crassa-aneuploidy; Histidine reversion-Ames test
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NCI Carcinogenesis Studies (gavage);no evidence:mouse,rat
NTP Carcinogenesis Studies (gavagae);no evidence:mouse,rat NTPTR* NTP-TR-403,1992
NTP Carcinogenesis studies; test completed (peer review), October 2000

Page last reviewed: November 16, 2018

Content source: National Institute for Occupational Safety and Health